<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653300</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-N01</org_study_id>
    <nct_id>NCT02653300</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)</brief_title>
  <official_title>An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, pilot study using the oral ORMD-0801 insulin formulation in patients with&#xD;
      NASH and confirmed type 2 DM or pre-diabetes. The study will consist of a Screening, placebo&#xD;
      run-in, treatment phase and end-of-study phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory study will first enroll 10 patients with NASH and type 2 DM, to evaluate the&#xD;
      safety of oral insulin and to measure the change in liver fat content.&#xD;
&#xD;
      At the completion of their 4-week follow-up period, results will be presented to the Helsinki&#xD;
      Committee. Following approval, an additional 20 patients will be enrolled. The size of the&#xD;
      study population was determined by the investigator (with literature review) to be sufficient&#xD;
      to show trends of reducing liver fat content by analysis of MRI PDFF (MRI-Proton Density Fat&#xD;
      Fraction) images, the FibroMax™ Test and Fibroscan® including Controlled Attenuation&#xD;
      Parameter (CAP™). CAP™ is a measure of the ultrasound attenuation to quantify steatosis in&#xD;
      the liver.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MRI-Proton Density Fat Fraction (MRI-PDFF)</measure>
    <time_frame>Two timepoints: Baseline (week 0) and Week 12</time_frame>
    <description>Absolute Change in MRI-Proton Density Fat Fraction (expressed as percent fat in the liver) from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Transient Elastography Measurement (Fibroscan)</measure>
    <time_frame>Two timepoints: Baseline (week 0) and Week 12</time_frame>
    <description>Mean Transient elasticity, measured in kPA (kilo Pascal),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Fibrosis Score CAP™ (FibroMax)</measure>
    <time_frame>Two timepoints: Baseline (week 0) and Week 12</time_frame>
    <description>Mean fibrosis score (severity scale of liver fibrosis) measured at baseline and week 12. Fibrosis Score CAP measures the amount of steatosis (fatty change) in the liver. The CAP score is measured in decibels per meter (dB/m). It ranges from 100 to 400 dB/m with higher values indicating more fatty change</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Non-Alcoholic Steatohepatitis (NASH)</condition>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Oral Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oral Insulin</intervention_name>
    <description>all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.</description>
    <arm_group_label>Oral Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known type 2 DM according to American Diabetic Association (one of the three needed):&#xD;
             Fasting Plasma Glucose ≥126 mg/dl or 2h postprandial (PG) following 75g OGTT ≥ 200&#xD;
             mg/dl or HbA1C &gt; 5.7% or on treatment with metformin&#xD;
&#xD;
          -  Abdominal ultrasound (US) proven fatty liver performed within 6 months before&#xD;
             randomization, confirmed by central US.&#xD;
&#xD;
          -  Fat concentration in the liver of S2 (moderate steatosis, 6-32% hepatocytes with&#xD;
             steatosis) or more as measured by Fibromax.&#xD;
&#xD;
          -  Signature of the written informed consent.&#xD;
&#xD;
          -  Negative pregnancy test at study entry for females of child bearing potential.&#xD;
&#xD;
          -  Females must have a negative urine pregnancy test result at screening, prior to the&#xD;
             start of the run-in period, and at initiation of active dosing. A negative urine and&#xD;
             serum pregnancy test must be obtained prior to active dosing. Males and females of&#xD;
             childbearing potential must use two methods of contraception.&#xD;
&#xD;
          -  Females of non-childbearing potential are defined as postmenopausal who a) had more&#xD;
             than 24 months since last menstrual cycle with menopausal levels of FSH, b) who are&#xD;
             surgically menopausal.&#xD;
&#xD;
          -  For hypertensive patients, hypertension must be controlled by stable dose of&#xD;
             anti-hypertensive medication for at least 2 months prior to screening with BP &lt;&#xD;
             150/&lt;95 mmHg&#xD;
&#xD;
          -  Patients previously treated with vitamin E (&gt;400IU/day).&#xD;
&#xD;
          -  Glycaemia must be controlled (Glycosylated Hemoglobin A1C ≤9%) while any HbA1C&#xD;
             increment should not exceed 1% during 6 months prior to enrolment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active (acute or chronic) liver disease other than NASH (e.g. viral&#xD;
             hepatitis, genetic hemochromatosis, Wilson disease, alpha 1antitripsin deficiency,&#xD;
             alcohol liver disease, drug induced liver disease) at the time of randomization.&#xD;
&#xD;
          -  ALT or AST ≥ 2 times ULN&#xD;
&#xD;
          -  Abnormal synthetic liver function (serum albumin ≤3.5gm%, INR &gt;1.3).&#xD;
&#xD;
          -  Known alcohol and/or any other drug abuse or dependence in the last five years.&#xD;
&#xD;
          -  Weight &gt;120 Kg&#xD;
&#xD;
          -  Known history or presence of clinically significant cardiovascular, gastrointestinal,&#xD;
             metabolic (other than diabetes mellitus), neurologic, pulmonary, endocrine,&#xD;
             psychiatric, neoplastic disorder or nephrotic syndrome.&#xD;
&#xD;
          -  History or presence of any disease or condition known to interfere with the&#xD;
             absorption, distribution, metabolism or excretion of drugs including bile salt&#xD;
             metabolites (e.g. inflammatory bowel disease (IBD), previous intestinal (ileal or&#xD;
             colonic) operation, chronic pancreatitis, celiac disease or previous vagotomy.&#xD;
&#xD;
          -  Weight loss of more than 5% within 6 months prior to randomization.&#xD;
&#xD;
          -  History of bariatric surgery.&#xD;
&#xD;
          -  Uncontrolled blood pressure BP ≥150/95.&#xD;
&#xD;
          -  Non type 2 DM (type I, endocrinopathy, genetic syndromes etc).&#xD;
&#xD;
          -  Patients with HIV.&#xD;
&#xD;
          -  Daily alcohol intake &gt;20 g/day for women and &gt;30 g/day for men.&#xD;
&#xD;
          -  Treatment anti-diabetic medications other than metformin, such as DPP-4 inhibitors,&#xD;
             GLP-1 receptor agonists, TZDs, etc.&#xD;
&#xD;
          -  Metformin, Fibrates, Statins, not provided on a stable dose in the last 6 months.&#xD;
&#xD;
          -  Patients who are treated with Valproic acid, Tamoxifen, Methotrexate, Amiodaron.&#xD;
&#xD;
          -  Chronic treatment with antibiotics (e.g. Rifaximin).&#xD;
&#xD;
          -  Homeopathic and/or Alternative treatments.&#xD;
&#xD;
          -  Uncontrolled hypothyroidism defined as Thyroid Stimulating Hormone &gt;2X the upper limit&#xD;
             of normal (UNLN).&#xD;
&#xD;
          -  Patients with renal dysfunction: eGFR&lt; 40 ml/min.&#xD;
&#xD;
          -  Unexplained serum creatinine phosphokinase&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rifaat Safadi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.</citation>
    <PMID>22488764</PMID>
  </reference>
  <reference>
    <citation>Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010 Aug;53(2):372-84. doi: 10.1016/j.jhep.2010.04.008. Epub 2010 May 7.</citation>
    <PMID>20494470</PMID>
  </reference>
  <reference>
    <citation>Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30. Review.</citation>
    <PMID>21623852</PMID>
  </reference>
  <reference>
    <citation>Lin SC, Heba E, Bettencourt R, Lin GY, Valasek MA, Lunde O, Hamilton G, Sirlin CB, Loomba R. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. Aliment Pharmacol Ther. 2017 Mar;45(6):844-854. doi: 10.1111/apt.13951. Epub 2017 Jan 24.</citation>
    <PMID>28116801</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 24, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <results_first_submitted>July 27, 2021</results_first_submitted>
  <results_first_submitted_qc>August 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2021</results_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Clinical Protocol ORA-D N01</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02653300/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Insulin</title>
          <description>treatment&#xD;
Oral Insulin: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Insulin</title>
          <description>treatment&#xD;
Oral Insulin: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>Kg/M^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.08" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in MRI-Proton Density Fat Fraction (MRI-PDFF)</title>
        <description>Absolute Change in MRI-Proton Density Fat Fraction (expressed as percent fat in the liver) from baseline to week 12</description>
        <time_frame>Two timepoints: Baseline (week 0) and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Insulin</title>
            <description>treatment&#xD;
Oral Insulin: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MRI-Proton Density Fat Fraction (MRI-PDFF)</title>
          <description>Absolute Change in MRI-Proton Density Fat Fraction (expressed as percent fat in the liver) from baseline to week 12</description>
          <units>percentage fat in the liver</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRPDFF (%) at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR PDFF (%) at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Mean Change in MR PDFF (%) from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03125</p_value>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Transient Elastography Measurement (Fibroscan)</title>
        <description>Mean Transient elasticity, measured in kPA (kilo Pascal),</description>
        <time_frame>Two timepoints: Baseline (week 0) and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Insulin</title>
            <description>treatment&#xD;
Oral Insulin: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Transient Elastography Measurement (Fibroscan)</title>
          <description>Mean Transient elasticity, measured in kPA (kilo Pascal),</description>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Fibrosis Score CAP™ (FibroMax)</title>
        <description>Mean fibrosis score (severity scale of liver fibrosis) measured at baseline and week 12. Fibrosis Score CAP measures the amount of steatosis (fatty change) in the liver. The CAP score is measured in decibels per meter (dB/m). It ranges from 100 to 400 dB/m with higher values indicating more fatty change</description>
        <time_frame>Two timepoints: Baseline (week 0) and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Insulin</title>
            <description>treatment&#xD;
Oral Insulin: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fibrosis Score CAP™ (FibroMax)</title>
          <description>Mean fibrosis score (severity scale of liver fibrosis) measured at baseline and week 12. Fibrosis Score CAP measures the amount of steatosis (fatty change) in the liver. The CAP score is measured in decibels per meter (dB/m). It ranges from 100 to 400 dB/m with higher values indicating more fatty change</description>
          <units>dB/M</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Fibrosis Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.5" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Fibrosis Score at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.5" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>twelve weeks (Baseline to 12 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Insulin</title>
          <description>treatment&#xD;
Oral Insulin: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a pilot study with ten subjects enrolled, and eight subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Miriam Kidron, Ph.D.</name_or_title>
      <organization>Oramed Pharmaceuticals</organization>
      <phone>+972-2-566-0100</phone>
      <email>miriam@oramed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

